Home

About Us

• About Us Overview
• Historical Timeline
• Executive Team
• Board of Directors
• Corporate Responsibility
  • Corporate Giving and Grants
    • Grant Request Form
    • Grant Guidelines
  • Prescriber Data Privacy
  • Code of Conduct
  • Compliance Reporting
  • Corporate Compliance
• Corporate Values
• Contact Us
  • Map and Directions

Products

• Products Overview
• Kidney Cancer
• Liver Cancer
• Patient Access

Development

• Development Overview
• Clinical Pipeline
• Nexavar (sorafenib)
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Thyroid Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Ovarian Cancer
• Carfilzomib
  • Multiple Myeloma
  • Solid Tumors
• ONX 0801
• ONX 0803 and ONX 0805
• ONX 0912 (formerly PR-047) and ONX 0914 (formerly PR-957)
• Cell Cycle Kinase Inhibitor

Investors

• Investors Overview
• Financial Information
• Stock Information
• Analyst Coverage
• Event Calendar
• Annual Report
• Proxy Materials
• SEC Filings
• Corporate Governance
  • Board of Directors
  • Board Committees
  • Code of Conduct
  • Trading Policy
• Information Request

News and Media

• News and Media Overview
• Press Releases
  • Current Press Releases
  • Press Releases 2009
  • Press Releases 2008
  • Press Releases 2007
  • Press Releases 2006
  • Press Releases 2005
• Online Media Kit

Careers

• Careers Overview
• Job Openings
• Benefits
• How to Apply
• Corporate Values